(19)
(11) EP 0 981 352 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.06.2009 Bulletin 2009/25

(45) Mention of the grant of the patent:
21.01.2009 Bulletin 2009/04

(21) Application number: 98920293.2

(22) Date of filing: 06.05.1998
(51) International Patent Classification (IPC): 
A61K 38/15(2006.01)
C07K 11/02(2006.01)
A61P 9/04(2006.01)
 A61K 45/06(2006.01)
A61P 9/00(2006.01)
A61P 9/06(2006.01)
(86) International application number:
PCT/US1998/009238
(87) International publication number:
WO 1998/050048 (12.11.1998 Gazette 1998/45)

(54)

Use of aplidine for the treatment of cardiovascular diseases

Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen

Utilisation d' aplidine pour le traitement des maladies cardio-vasculaires

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 07.05.1997 US 45803 P

(43) Date of publication of application:
01.03.2000 Bulletin 2000/09

(73) Proprietors:
  • PHARMA MAR, S.A.
    28760 Tres Cantos, Madrid (ES)
  • Crumb, William J.
    Metairie, LA 70005 (US)

(72) Inventors:
  • CRUMB, William, J.
    Metairie, LA 70005 (US)
  • FAIRCLOTH, Glynn, T.
    Cambridge, MA 02142 (US)

(74) Representative: Ruffles, Graham Keith et al
Marks & Clerk LLP 62-68 Hills Road
Cambridge CB2 1LA
Cambridge CB2 1LA (GB)


(56) References cited: : 
WO-A-91/04985
 US-A- 5 580 871
   
  • SCHRAMM M ET AL: "Modulation of calcium channel function by drugs." LIFE SCIENCES 18 NOV 1985, vol. 37, no. 20, 18 November 1985 (1985-11-18), pages 1843-1860, XP002419951 ISSN: 0024-3205
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).